ARTICLE | Clinical News
GEM 91 antisense oligonucleotide: Began a Phase I trial.
October 18, 1993 7:00 AM UTC
Hybridon Inc. Product: GEM 91 antisense oligonucleotide Indication: Treatment of HIV/ AIDS Status: Began a Phase I trial in 24 patients in France ...